MMWR Vol. 62 / No. RR-9

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

If you have trouble reading this e-mail, please click here.

HHS, CDC and MMWR Logos

Recommendations and Reports
Volume 62, No. RR-9
October 25, 2013

PDF of this issue

Earn CE

MMWR Online

Subscriptions

Contact MMWR

CDC Homepage

MMWR RSS feeds MMWR RSS Feed
How to Add MMWR RSS feeds
Learn More About RSS
 
Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis
 
The Food and Drug Administration (FDA) has approved use of bedaquiline
fumarate (Sirturo or bedaquiline)
for treatment of multidrug-resistant tuberculosis (MDR TB) in certain persons under
the provisions of the accelerated
approval regulations for “Serious or
Life-Threatening Illnesses.” This report provides provisional CDC guidance for the use and safety monitoring of bedaquiline in persons who receive a diagnosis of MDR TB. These guidelines are intended for health-care professionals who might use bedaquiline
for the treatment of MDR TB.
full textfull text
 

Department of Health and Human Services
Centers for Disease Control and Prevention